


10/524204  
DT01 Rec'd PCT/PTO 10 FEB 2005

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently amended) A method of treating or preventing a disease or condition in which the inhibition of kinase Itk activity is beneficial comprising administering ~~The use of a~~ compound of formula (I)



(I)

wherein:

R<sup>3</sup> represents halogen, CN, C1 to 3 alkyl or C1 to 3 alkoxy;

Ar represents phenyl, a 5- or 6-membered heteroaromatic ring or an indole ring; said heteroaromatic ring incorporating 1 to 3 heteroatoms independently selected from O, N and S;

R<sup>1</sup> represents H, halogen, CN, C1 to 6 alkyl, NO<sub>2</sub>, SO<sub>2</sub>Me, C1 to 6 alkynyl, CH<sub>2</sub>OH, OR<sup>2</sup>, (CH<sub>2</sub>)<sub>n</sub>NR<sup>4</sup>R<sup>5</sup> or phenyl optionally substituted by NH<sub>2</sub>;

m represents an integer 1 or 2; and when m represents 2, each  $R^1$  may be selected independently;

n represents an integer 0 or 1;

$R^2$  represents H or C1 to 4 alkyl; said C1 to 4 alkyl being optionally further substituted by a group selected from  $Ar^1$ ,  $CONH_2$ ,  $CO_2Et$ , OH,  $NR^6R^7$ , halogen and epoxy; and when substituted by  $NR^6R^7$  or halogen, said alkyl is optionally further substituted by OH;

$R^4$  represents H, C1 to 4 alkyl or  $CH_2Ar^2$ ;

$R^5$  represents H, C1 to 6 alkyl, C2 to 6 alkanoyl,  $SO_2-Ar^5$  or  $CH_2Ar^2$ ; said alkyl group being optionally further substituted by a 5 to 7 membered saturated azacyclic ring optionally incorporating one additional heteroatom selected from O, S and  $NR^8$ ;

or the group  $-NR^4R^5$  together represents a 5 to 7 membered saturated azacyclic ring optionally incorporating one additional heteroatom selected from O, S and  $NR^8$ ;

$R^6$  represents H, C1 to 4 alkyl or  $CH_2CH_2OCH_3$ ;

$R^7$  represents H, C1 to 6 alkyl, C3 to 6 cycloalkyl,  $Ar^3$ , a 5 or 6 membered saturated or partially unsaturated heterocyclic ring incorporating 1 or 2 heteroatoms selected independently from O, N and S and optionally substituted by Me, Et or  $CO_2Et$ ; said C1 to 6 alkyl being optionally substituted by one or more groups selected independently from OH, CN,  $CONMe_2$ ,  $CONHMe$ ,

C1 to 4 alkoxy, halogen,  $\text{NMe}_2$ ,  $\text{Ar}^4$ , and a 5 or 6 membered saturated heterocyclic ring incorporating 1 or 2 heteroatoms selected independently from O, N and S and optionally also incorporating a carbonyl group; said C3 to 6 cycloalkyl being optionally substituted by OH or CN;

or the group  $-\text{NR}^6\text{R}^7$  together represents a 5 to 7 membered saturated azacyclic ring optionally incorporating 1 additional heteroatom selected from O and  $\text{NR}^9$ ; and optionally substituted by one or more substituents selected independently from OH,  $\text{NMe}_2$ ,  $\text{CONH}_2$ ,  $\text{CH}_2\text{OH}$ ,  $\text{CH}_2\text{CH}_2\text{OH}$ , phenyl, pyridyl, piperidiny1 or methoxyphenyl;

$\text{R}^8$  represents H, C1 to 6 alkyl or  $\text{CH}_2\text{Ph}$ ;

$\text{R}^9$  represents  $\text{CH}_2\text{CH}_2\text{OH}$ ,  $\text{COCH}_3$ , Me,  $\text{CO}_2\text{Et}$ ,  $\text{CH}_2\text{CH}_2\text{OMe}$  or a six membered aromatic or azaaromatic ring optionally further substituted by one or more substituents selected independently from Cl, CN, OMe and  $\text{CF}_3$ ;

$\text{R}^{10}$  represents H, halogen, CN, C1 to 4 alkyl, C1 to 4 alkoxy,  $\text{NR}^{14}\text{R}^{15}$  or a group  $-\text{X}-\text{Y}-\text{Z}$ ;

$\text{R}^{14}$  and  $\text{R}^{15}$  independently represent H or C1 to 4 alkyl; said alkyl being optionally further substituted by OH;

X represents O, S, a bond or  $\text{NR}^{16}$  wherein  $\text{R}^{16}$  represents H or C1 to 4 alkyl; said alkyl being optionally further substituted by OH;

Y represents C1 to 4 alkyl or a bond;

Z represents:

- i) phenyl, naphthyl or a 5- or 6-membered heteroaromatic ring system containing one to three heteroatoms independently selected from O, N and S; or
- ii) a five- or six-membered saturated heterocyclic ring containing one or two heteroatoms independently selected from O, N and S; said ring optionally being benzo fused; or
- iii) C3 to 6 cycloalkyl;

said ring Z being optionally substituted by one or more substituents independently selected from halogen, OH, C1 to 4 alkyl, C1 to 4 alkoxy, hydroxymethyl, methylsulphonyl and  $\text{NR}^{17}\text{R}^{18}$ ;

$\text{R}^{17}$  and  $\text{R}^{18}$  independently represent H, C1 to 4 alkyl, formyl or C2 to 4 alkanoyl; or the group  $\text{NR}^{17}\text{R}^{18}$  together represents a saturated 5 to 7 membered azacyclic ring optionally containing one further heteroatom selected from O, N and S;

$\text{Ar}^1$  represents phenyl, thiazolyl or thiadiazolyl, optionally further substituted by halogen;

$\text{Ar}^2$  represents phenyl, a 5- or 6-membered heteroaromatic ring or a benzimidazole ring; said heteroaromatic ring incorporating 1 to 3 heteroatoms independently selected from O, N and S; said phenyl or heteroaromatic or benzimidazole ring being optionally further substituted by one or two groups independently selected from halogen, C1 to 4 alkyl, CN,  $\text{CH}_2\text{OH}$ , C1 to 4 alkoxy,  $\text{CO}_2\text{Me}$ ,  $\text{CH}_2\text{OAc}$  and pyridyl;

$\text{Ar}^3$  represents thiazolyl, triazolyl or tetrazolyl;

Ar<sup>4</sup> represents phenyl, a 5- or 6-membered heteroaromatic ring or an indole ring; said heteroaromatic ring incorporating 1 to 3 heteroatoms independently selected from O, N and S; said phenyl, heteroaromatic or indole ring being optionally further substituted by one or two groups independently selected from halogen and OMe;

Ar<sup>5</sup> represents phenyl, a 5- or 6-membered heteroaromatic ring or a quinoline ring; said heteroaromatic ring incorporating 1 to 3 heteroatoms independently selected from O, N and S; said phenyl or heteroaromatic or quinoline ring being optionally further substituted by halogen, C1 to 4 alkyl, CN, C1 to 4 alkoxy, and OCH<sub>2</sub>CH<sub>2</sub>CN;

or a pharmaceutically acceptable salt thereof; ~~in the manufacture of a medicament for the treatment or prophylaxis of diseases or conditions in which inhibition of kinase Itk activity is beneficial.~~

2. (Currently amended) The ~~use~~ method according to Claim 1 ~~of a compound of formula (I) or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment or prophylaxis of,~~ wherein the disease or condition is a Th2-driven and/or mast cell-driven and/or basophil driven disease or condition ~~diseases or conditions.~~

3. (Currently amended) The ~~use~~ method according to Claim 2 wherein the disease is asthma.

4. (Currently amended) The ~~use~~ method according to Claim 2 wherein the disease is allergic rhinitis.


5. (Currently amended) The ~~use~~ method according to ~~any one of Claims 1 to 4~~ Claim 1 wherein R<sup>3</sup> in formula (I) represents halogen.

6. (Currently amended) The ~~use~~ method according to ~~any one of Claims 1 to 4~~ Claim 1 wherein Ar in formula (I) represents phenyl.

7. (Currently amended) The ~~use~~ method according to ~~any one of Claims 1 to 6~~ Claim 1 wherein  $R^1$  in formula (I) represents  $OR^2$  or  $(CH_2)_nNR^4R^5$ .

8. (Currently amended) The ~~use~~ method according to ~~any one of Claims 1 to 6~~ Claim 1 wherein  $R^{10}$  represents halogen, CN, C1 to 4 alkyl, C1 to 4 alkoxy,  $NR^{14}R^{15}$  or a group  $-X-Y-Z$ .

9. (Original) A compound of formula (Ia)



(Ia)

wherein:

$R^3$  represents halogen, C1 to 3 alkyl or C1 to 3 alkoxy;

$R^{10}$  represents H;

Ar represents phenyl, a 5- or 6-membered heteroaromatic ring or an indole ring; said heteroaromatic ring incorporating 1 to 3 heteroatoms independently selected from O, N and S;  
m represents an integer 1 or 2;

when m represents 1,  $R^1$  represents  $(CH_2)_nNR^4R^5$  and n represents an integer 0 or 1;

when m represents 2, one R<sup>1</sup> represents chloro or OMe and the other R<sup>1</sup> represents

(CH<sub>2</sub>)<sub>n</sub>NR<sup>4</sup>R<sup>5</sup> and n represents an integer 0 or 1;

R<sup>4</sup> represents H or C1 to 4 alkyl;

R<sup>5</sup> represents CH<sub>2</sub>Ar<sup>2</sup>;

Ar<sup>2</sup> represents phenyl, a 5- or 6-membered heteroaromatic ring or a benzimidazole ring; said heteroaromatic ring incorporating 1 to 3 heteroatoms independently selected from O, N and S; said phenyl, heteroaromatic or benzimidazole ring being optionally further substituted by one or two groups independently selected from halogen, C1 to 4 alkyl, CN, CH<sub>2</sub>OH, C1 to 4 alkoxy, CO<sub>2</sub>Me, CH<sub>2</sub>OAc and pyridyl;  
or a pharmaceutically acceptable salt thereof.


10. (Original) A compound according to Claim 9 that is:

4-({[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenyl]amino}methyl)benzonitrile  
N-benzyl-N-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenyl]amine  
N-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenyl]-N-(1H-imidazol-2-ylmethyl)amine  
N-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenyl]-N-(1H-imidazol-5-ylmethyl)amine  
3-({[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenyl]amino}methyl)benzonitrile  
N-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenyl]-N-(4-methoxybenzyl)amine  
N-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenyl]-N-(2-methoxybenzyl)amine  
N-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenyl]-N-(3-methoxybenzyl)amine  
N-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenyl]-N-(2-chlorobenzyl)amine  
N-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenyl]-N-(4-chlorobenzyl)amine  
N-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenyl]-N-(1H-pyrazol-3-ylmethyl)amine  
N-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenyl]-N-(3-chlorobenzyl)amine  
[5-({[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenyl]amino}methyl)-2-furyl]methanol  
N-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenyl]-N-(thien-2-ylmethyl)amine

*N*-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]-*N*-(2-furylmethyl)amine  
*N*-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]-*N*-(thien-3-ylmethyl)amine  
*N*-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]-*N*-[(4-methyl-1*H*-imidazol-5-yl)methyl]amine  
*N*-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]-*N*-(3-furylmethyl)amine  
*N*-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]-*N*-(1,3-thiazol-2-ylmethyl)amine  
*N*-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]-*N*-[(4-bromothien-2-yl)methyl]amine  
*N*-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]-*N*-(1*H*-imidazol-4-ylmethyl)amine  
*N*-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]-*N*-[(2-methyl-1*H*-imidazol-5-yl)methyl]amine  
*N*-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]-*N*-[(3,5-dimethylisoxazol-4-yl)methyl]amine  
[5-( {[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]amino } methyl)-2-furyl]methyl acetate  
*N*-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]-*N*-[(5-pyridin-2-ylthien-2-yl)methyl]amine  
*N*-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]-*N*-[(1-methyl-1*H*-benzimidazol-2-yl)methyl]amine  
*N*-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]-*N*-[(2-ethyl-1*H*-imidazol-5-yl)methyl]amine  
*N*-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]-*N*-[(1-methyl-1*H*-imidazol-5-yl)methyl]amine  
methyl 4-( {[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]amino } methyl)-1-methyl-1*H*-pyrrole-2-carboxylate  
*N*-benzyl-5-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)pyridin-2-amine  
5-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)-*N*-(3-methoxybenzyl)pyridin-2-amine  
or a pharmaceutically acceptable salt thereof.

11. (Original) A compound of formula (Ib)





(1b)

wherein:

R<sup>3</sup> represents halogen, C1 to 3 alkyl or C1 to 3 alkoxy;

R<sup>10</sup> represents H;

Ar represents phenyl, a 5- or 6-membered heteroaromatic ring or an indole ring; said heteroaromatic ring incorporating 1 to 3 heteroatoms independently selected from O, N and S; m represents an integer 1 or 2;

when m represents 1, R<sup>1</sup> represents OR<sup>2</sup>;

when m represents 2, one R<sup>1</sup> represents chloro or OMe and the other R<sup>1</sup> represents OR<sup>2</sup>;

R<sup>2</sup> represents C3 to 4 alkyl substituted by NR<sup>6</sup>R<sup>7</sup> and by OH;

R<sup>6</sup> represents H, C1 to 4 alkyl or CH<sub>2</sub>CH<sub>2</sub>OCH<sub>3</sub>;

R<sup>7</sup> represents H, C1 to 6 alkyl, C3 to 6 cycloalkyl, Ar<sup>3</sup>, a 5 or 6 membered saturated or partially unsaturated heterocyclic ring incorporating 1 or 2 heteroatoms selected independently from O, N and S and optionally substituted by Me, Et or CO<sub>2</sub>Et; said C1 to 6 alkyl being optionally substituted by one or more groups selected independently from OH, CN, CONMe<sub>2</sub>, CONHMe, C1 to 4 alkoxy, halogen, NMe<sub>2</sub>, Ar<sup>4</sup>, and a 5 or 6 membered saturated heterocyclic ring incorporating 1 or 2 heteroatoms selected independently from O, N and S and optionally also incorporating a carbonyl group; said C3 to 6 cycloalkyl being optionally substituted by OH or CN;

or the group -NR<sup>6</sup>R<sup>7</sup> together represents a 5 to 7 membered saturated azacyclic ring optionally incorporating 1 additional heteroatom selected from O and NR<sup>9</sup>; and optionally substituted by one or more substituents selected independently from OH, NMe<sub>2</sub>, CONH<sub>2</sub>, CH<sub>2</sub>OH, CH<sub>2</sub>CH<sub>2</sub>OH, phenyl, pyridyl, piperidinyl and methoxyphenyl;

R<sup>9</sup> represents CH<sub>2</sub>CH<sub>2</sub>OH, COCH<sub>3</sub>, Me, CO<sub>2</sub>Et, CH<sub>2</sub>CH<sub>2</sub>OMe or a six membered aromatic or azaaromatic ring optionally further substituted by one or more substituents selected independently from Cl, CN, OMe and CF<sub>3</sub>;

Ar<sup>3</sup> represents thiazolyl, triazolyl or tetrazolyl;

Ar<sup>4</sup> represents phenyl, a 5- or 6-membered heteroaromatic ring or an indole ring; said heteroaromatic ring incorporating 1 to 3 heteroatoms independently selected from O, N and S; said phenyl, heteroaromatic or indole ring being optionally further substituted by one or two groups independently selected from halogen and OMe; or a pharmaceutically acceptable salt thereof.

12. (Original) A compound according to Claim 11 that is:

1-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-3-pyrrolidin-1-ylpropan-2-ol  
1-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-3-morpholin-4-ylpropan-2-ol  
1-{3-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-2-hydroxypropyl}pyrrolidin-3-ol  
1-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-3-piperidin-1-ylpropan-2-ol  
1-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-3-(diethylamino)propan-2-ol  
1-{3-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-2-hydroxypropyl}piperidin-4-ol  
1-(4-acetylpiperazin-1-yl)-3-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]propan-2-ol  
1-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-3-[3-(dimethylamino)pyrrolidin-1-yl]propan-2-ol  
4-[(2-hydroxy-3-[4-(6-methyl-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]propyl)amino)methyl]phenol

1-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-3-[(2-hydroxyethyl)(methyl)amino]propan-2-ol  
3-[{3-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-2-hydroxypropyl}(methyl)amino]propanenitrile  
4-{3-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-2-hydroxypropyl}piperazin-1-ol  
*N*<sup>2</sup>-{3-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-2-hydroxypropyl}-*N*<sup>1</sup>,*N*<sup>1</sup>,*N*<sup>2</sup>-trimethylglycinamide  
1-[benzyl(methyl)amino]-3-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]propan-2-ol  
1-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-3-[methyl(2-phenylethyl)amino]propan-2-ol  
1-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-3-(4-phenylpiperazin-1-yl)propan-2-ol  
1-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-3-(4-pyridin-2-ylpiperazin-1-yl)propan-2-ol  
1-[2-({3-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-2-hydroxypropyl}amino)ethyl]imidazolidin-2-one  
1-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-3-[(3-methoxybenzyl)amino]propan-2-ol  
1-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-3-[(2-chlorobenzyl)amino]propan-2-ol  
1-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-3-[(4-chlorobenzyl)amino]propan-2-ol  
1-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-3-[(3-chlorobenzyl)amino]propan-2-ol  
ethyl 4-({3-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-2-hydroxypropyl}amino)piperidine-1-carboxylate  
1-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-3-[4-(2-methoxyethyl)piperazin-1-yl]propan-2-ol  
1-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-3-(cyclopropylamino)propan-2-ol  
3-({3-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-2-hydroxypropyl}amino)propan-2-ol  
1-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-3-[(2-methoxyethyl)amino]propan-2-ol

2-({3-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-2-hydroxypropyl} amino)propan-1-ol

1-(benzylamino)-3-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]propan-2-ol

1-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-3-[(pyridin-3-ylmethyl)amino]propan-2-ol

1-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-3-[(pyridin-4-ylmethyl)amino]propan-2-ol

1-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-3-[(1-ethylpiperidin-3-yl)amino]propan-2-ol

1-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-3-[(2-morpholin-4-ylethyl)amino]propan-2-ol

1-[3-({3-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-2-hydroxypropyl} amino)propyl]pyrrolidin-2-one

1-{3-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-2-hydroxypropyl}piperidin-3-ol

1-{3-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-2-hydroxypropyl}prolinamide

1-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-3-[4-(hydroxymethyl)piperidin-1-yl]propan-2-ol

1-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-3-[2-(hydroxymethyl)piperidin-1-yl]propan-2-ol

1-{3-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-2-hydroxypropyl}piperidine-4-carboxamide


1-{3-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-2-hydroxypropyl}piperidine-3-carboxamide

1-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-3-[4-(2-hydroxyethyl)piperazin-1-yl]propan-2-ol

2-(4-{3-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-2-hydroxypropyl}piperazin-1-yl)benzonitrile

6-(4-{3-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-2-hydroxypropyl}piperazin-1-yl)nicotinonitrile  
1-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-3-(1,3-thiazol-2-ylamino)propan-2-ol  
1-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-3-(4-pyrazin-2-ylpiperazin-1-yl)propan-2-ol  
1-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-3-[(2-methoxybenzyl)amino]propan-2-ol  
4-[{3-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-2-hydroxypropyl}(methyl)amino]cyclohexanecarbonitrile  
1-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-3-(2-pyridin-3-ylpiperidin-1-yl)propan-2-ol  
1-{3-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-2-hydroxypropyl}-4-phenylpiperidin-4-ol  
2-({3-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-2-hydroxypropyl} amino)-3-methylbutan-1-ol  
1-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-3-[4-(3-methoxyphenyl)piperazin-1-yl]propan-2-ol  
or a pharmaceutically acceptable salt thereof.

13. (Original) A compound of formula (Ic)



(Ic)

wherein:

$R^3$  represents halogen, C1 to 3 alkyl or C1 to 3 alkoxy;

$R^{10}$  represents H;

Ar represents phenyl, a 5- or 6-membered heteroaromatic ring or an indole ring; said heteroaromatic ring incorporating 1 to 3 heteroatoms independently selected from O, N and S; m represents an integer 1 or 2;

when m represents 1,  $R^1$  represents  $OR^2$ ;

when m represents 2, one  $R^1$  represents chloro,  $NO_2$  or OMe and the other  $R^1$  represents  $OR^2$ ;

$R^2$  represents C2 to 4 alkyl substituted by a group  $NR^6R^7$ ;

$R^6$  represents H, C1 to 4 alkyl or  $CH_2CH_2OCH_3$ ;

$R^7$  represents H, C1 to 6 alkyl, C3 to 6 cycloalkyl,  $Ar^3$ , a 5 or 6 membered saturated or partially unsaturated heterocyclic ring incorporating 1 or 2 heteroatoms selected independently from O, N and S and optionally substituted by Me, Et or  $CO_2Et$ ; said C1 to 6 alkyl being optionally substituted by one or more groups selected independently from OH, CN,  $CONMe_2$ ,  $CONHMe$ , C1 to 4 alkoxy, halogen,  $NMe_2$ ,  $Ar^4$ , and a 5 or 6 membered saturated heterocyclic ring incorporating 1 or 2 heteroatoms selected independently from O, N and S and optionally also incorporating a carbonyl group; said C3 to 6 cycloalkyl being optionally substituted by OH or CN;

or the group  $-NR^6R^7$  together represents a 5 or 6 membered saturated azacyclic ring optionally incorporating 1 additional heteroatom selected from O and  $NR^9$ ; and optionally substituted by one or more substituents selected independently from OH,  $NMe_2$ ,  $CONH_2$ ,  $CH_2OH$ ,  $CH_2CH_2OH$ , phenyl, pyridyl, piperidiny1 or methoxyphenyl;

$R^9$  represents  $CH_2CH_2OH$ ,  $COCH_3$ , Me,  $CO_2Et$ ,  $CH_2CH_2OMe$  or a six membered aromatic or azaaromatic ring optionally further substituted by one or more substituents selected independently from Cl, CN, OMe and  $CF_3$ ;

$Ar^3$  represents thiazolyl, triazolyl or tetrazolyl;

$Ar^4$  represents phenyl, a 5- or 6-membered heteroaromatic ring or an indole ring; said heteroaromatic ring incorporating 1 to 3 heteroatoms independently selected from O, N and S; said phenyl, heteroaromatic or indole ring being optionally further substituted by one or two groups independently selected from halogen and OMe; or a pharmaceutically acceptable salt thereof, with the provisos that:

- i) when  $R^6$  represents H or C1 to 4 alkyl,  $R^3$  does not represent unsubstituted C1 to 4 alkyl; and
- ii) that the group  $-NR^6R^7$  does not represent unsubstituted morpholine, thiomorpholine, 4-methylpiperazine or 4-phenylpiperazine.

14. (Original) A compound according to Claim 13 that is:

6-bromo-2-[4-(2-{4-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl}ethoxy)phenyl]-3H-imidazo[4,5-b]pyridine

6-bromo-2-[4-(2-piperidin-1-ylethoxy)phenyl]-3H-imidazo[4,5-b]pyridine

6-bromo-2-[4-(3-piperidin-1-ylpropoxy)phenyl]-3H-imidazo[4,5-b]pyridine

6-bromo-2-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]-3H-imidazo[4,5-b]pyridine

*N*-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-*N*-(tetrahydrofuran-2-ylmethyl)amine

6-bromo-2-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-3H-imidazo[4,5-b]pyridine

2-[{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}(methyl)amino]ethanol

3-[{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}(methyl)amino]propanenitrile

1-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}pyrrolidin-3-ol  
1-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-N,N-dimethylpyrrolidin-3-amine  
N-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-N,1-dimethylpyrrolidin-3-amine  
N~2~-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-N~1~,N~1~,N~2~-trimethylglycinamide  
N-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-N-ethyl-N',N'-dimethylethane-1,2-diamine  
N-benzyl-N-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-N-methylamine  
2-{4-[2-(4-acetylpiperazin-1-yl)ethoxy]phenyl}-6-bromo-3H-imidazo[4,5-b]pyridine  
N-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-N,N-bis(2-methoxyethyl)amine  
N-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-N-methyl-N-(2-phenylethyl)amine  
6-bromo-2-{4-[2-(4-pyridin-2-ylpiperazin-1-yl)ethoxy]phenyl}-3H-imidazo[4,5-b]pyridine  
N-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-N-[3-(1H-imidazol-1-yl)propyl]amine  
N-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-N-(4-methoxybenzyl)amine  
N-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-N-(3-methoxybenzyl)amine  
N-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-N-(4-chlorobenzyl)amine  
N-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-N-(3-chlorobenzyl)amine  
ethyl 4-({2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}amino)piperidine-1-carboxylate  
6-bromo-2-(4-{2-[4-(2-methoxyethyl)piperazin-1-yl]ethoxy}phenyl)-3H-imidazo[4,5-b]pyridine  
1-({2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}amino)propan-2-ol  
N-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-N-(2-methoxyethyl)amine  
2-({2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}amino)propan-1-ol



N-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-N-(2-furylmethyl)amine

N-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-N-(tetrahydrofuran-2-ylmethyl)amine

N-benzyl-N-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}amine

N-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-N-(pyridin-3-ylmethyl)amine

N-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-N-(pyridin-4-ylmethyl)amine

N-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-N-(thien-2-ylmethyl)amine

N-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-N-(1-phenylethyl)amine

N-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-1-ethylpiperidin-3-amine

N-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-N-(2-morpholin-4-ylethyl)amine

N-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-N-(2-methoxybenzyl)amine

1-[3-({2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}amino)propyl]pyrrolidin-2-one

N-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-N-[2-(4-chlorophenyl)ethyl]amine

4-[{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}(methyl)amino]cyclohexanecarbonitrile

1-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}piperidin-3-ol

6-bromo-2-{4-[2-(2-pyridin-3-ylpiperidin-1-yl)ethoxy]phenyl}-3H-imidazo[4,5-b]pyridine

N-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-N-cyclopentylamine

1-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-4-phenylpiperidin-4-ol

N-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-N-[2-(1H-imidazol-4-yl)ethyl]amine

1-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}piperidine-3-carboxamide

6-bromo-2-{4-[2-(4-pyrazin-2-ylpiperazin-1-yl)ethoxy]phenyl}-3H-imidazo[4,5-b]pyridine

(1*S*,2*S*)-2-({2-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]ethyl}amino)cyclohexanol

6-bromo-2-(4-{2-[4-(3-methoxyphenyl)piperazin-1-yl]ethoxy}phenyl)-3H-imidazo[4,5-b]pyridine

(1-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}piperidin-4-yl)methanol

4-({2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}amino)cyclohexanol

(1-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}piperidin-2-yl)methanol

1'-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-1,4'-bipiperidine

N-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-1,3-thiazol-2-amine

1-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}piperidine-4-carboxamide

N-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-1H-1,2,4-triazol-3-amine

2-(4-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}piperazin-1-yl)benzonitrile

6-(4-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}piperazin-1-yl)nicotinonitrile

1-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}prolinamide

6-bromo-2-(4-{2-[4-(2-methoxyphenyl)piperidin-1-yl]ethoxy}phenyl)-3H-imidazo[4,5-b]pyridine

2-(4-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}piperazin-1-yl)ethanol

1-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}piperidin-4-ol

6-bromo-2-(4-{2-[4-(2-methoxyphenyl)piperazin-1-yl]ethoxy}phenyl)-3H-imidazo[4,5-b]pyridine

(2*S*)-2-({2-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]ethyl}amino)-3-methylbutan-1-ol

N-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-4,5-dihydro-1,3-thiazol-2-amine

N-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-N-[2-(1H-indol-3-yl)ethyl]amine


(2*S*)-2-({2-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]ethyl}amino)-2-phenylethanol

N-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-1H-tetrazol-5-amine

(1*S*,2*R*)-2-({2-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]ethyl}amino)cyclohexanol

6-chloro-2-[4-(2-piperidin-1-ylethoxy)phenyl]-3H-imidazo[4,5-b]pyridine  
6-bromo-2-[4-(2-morpholin-4-ylethoxy)-3-nitrophenyl]-3H-imidazo[4,5-b]pyridine  
or a pharmaceutically acceptable salt thereof.

15. (Original) A compound of formula (Id)



(Id)

wherein:

R<sup>3</sup> represents halogen, CN, C1 to 3 alkyl or C1 to 3 alkoxy;

Ar represents phenyl, a 5- or 6-membered heteroaromatic ring or an indole ring; said heteroaromatic ring incorporating 1 to 3 heteroatoms independently selected from O, N and S;

R<sup>1</sup> represents H, halogen, CN, C1 to 6 alkyl, NO<sub>2</sub>, SO<sub>2</sub>Me, C1 to 6 alkynyl, CH<sub>2</sub>OH, OR<sup>2</sup>, (CH<sub>2</sub>)<sub>n</sub>NR<sup>4</sup>R<sup>5</sup> or phenyl optionally substituted by NH<sub>2</sub>;

m represents an integer 1 or 2; and when m represents 2, each R<sup>1</sup> may be selected independently;

n represents an integer 0 or 1;

R<sup>2</sup> represents H or C1 to 4 alkyl; said C1 to 4 alkyl being optionally further substituted by a group selected from Ar<sup>1</sup>, CONH<sub>2</sub>, CO<sub>2</sub>Et, OH, NR<sup>6</sup>R<sup>7</sup>, halogen and epoxy; and when substituted by NR<sup>6</sup>R<sup>7</sup> or halogen, said alkyl is optionally further substituted by OH;

R<sup>4</sup> represents H, C1 to 4 alkyl or CH<sub>2</sub>Ar<sup>2</sup>;

$R^5$  represents H, C1 to 6 alkyl, C2 to 6 alkanoyl,  $SO_2-Ar^5$  or  $CH_2Ar^2$ ; said alkyl group being optionally further substituted by a 5 to 7 membered saturated azacyclic ring optionally incorporating one additional heteroatom selected from O, S and  $NR^8$ ;

or the group  $-NR^4R^5$  together represents a 5 to 7 membered saturated azacyclic ring optionally incorporating one additional heteroatom selected from O, S and  $NR^8$ ;

$R^6$  represents H, C1 to 4 alkyl or  $CH_2CH_2OCH_3$ ;

$R^7$  represents H, C1 to 6 alkyl, C3 to 6 cycloalkyl,  $Ar^3$ , a 5 or 6 membered saturated or partially unsaturated heterocyclic ring incorporating 1 or 2 heteroatoms selected independently from O, N and S and optionally substituted by Me, Et or  $CO_2Et$ ; said C1 to 6 alkyl being optionally substituted by one or more groups selected independently from OH, CN,  $CONMe_2$ ,  $CONHMe$ , C1 to 4 alkoxy, halogen,  $NMe_2$ ,  $Ar^4$ , and a 5 or 6 membered saturated heterocyclic ring incorporating 1 or 2 heteroatoms selected independently from O, N and S and optionally also incorporating a carbonyl group; said C3 to 6 cycloalkyl being optionally substituted by OH or CN;

or the group  $-NR^6R^7$  together represents a 5 to 7 membered saturated azacyclic ring optionally incorporating 1 additional heteroatom selected from O and  $NR^9$ ; and optionally substituted by one or more substituents selected independently from OH,  $NMe_2$ ,  $CONH_2$ ,  $CH_2OH$ ,

$CH_2CH_2OH$ , phenyl, pyridyl, piperidiny1 or methoxyphenyl;

$R^8$  represents H, C1 to 6 alkyl or  $CH_2Ph$ ;

$R^9$  represents  $CH_2CH_2OH$ ,  $COCH_3$ , Me,  $CO_2Et$ ,  $CH_2CH_2OMe$  or a six membered aromatic or azaaromatic ring optionally further substituted by one or more substituents selected independently from Cl, CN, OMe and  $CF_3$ ;

$R^{10}$  represents halogen, CN, C1 to 4 alkyl, C1 to 4 alkoxy,  $NR^{14}R^{15}$  or a group  $-X-Y-Z$ ;

$R^{14}$  and  $R^{15}$  independently represent H or C1 to 4 alkyl; said alkyl being optionally further substituted by OH;

X represents O, S, a bond or  $NR^{16}$  wherein  $R^{16}$  represents H or C1 to 4 alkyl; said alkyl being optionally further substituted by OH;

Y represents C1 to 4 alkyl or a bond;

Z represents:

- i) phenyl, naphthyl or a 5- or 6-membered heteroaromatic ring system containing one to three heteroatoms independently selected from O, N and S; or
- ii) a five- or six-membered saturated heterocyclic ring containing one or two heteroatoms independently selected from O, N and S; said ring optionally being benzo fused; or

iii) C3 to 6 cycloalkyl;

said ring Z being optionally substituted by one or more substituents independently selected from halogen, OH, C1 to 4 alkyl, C1 to 4 alkoxy, hydroxymethyl, methylsulphonyl and  $NR^{17}R^{18}$ ;

$R^{17}$  and  $R^{18}$  independently represent H, C1 to 4 alkyl, formyl or C2 to alkanoyl; or the group  $NR^{17}R^{18}$  together represents a saturated 5 to 7 membered azacyclic ring optionally containing one further heteroatom selected from O, N and S;

$Ar^1$  represents phenyl, thiazolyl or thiadiazolyl, optionally further substituted by halogen;

$Ar^2$  represents phenyl, a 5- or 6-membered heteroaromatic ring or a benzimidazole ring; said heteroaromatic ring incorporating 1 to 3 heteroatoms independently selected from O, N and S; said phenyl or heteroaromatic or benzimidazole ring being optionally further substituted by one or two groups independently selected from halogen, C1 to 4 alkyl, CN,  $CH_2OH$ , C1 to 4 alkoxy,  $CO_2Me$ ,  $CH_2OAc$  and pyridyl;

$Ar^3$  represents thiazolyl, triazolyl or tetrazolyl;

Ar<sup>4</sup> represents phenyl, a 5- or 6-membered heteroaromatic ring or an indole ring; said heteroaromatic ring incorporating 1 to 3 heteroatoms independently selected from O, N and S; said phenyl, heteroaromatic or indole ring being optionally further substituted by one or two groups independently selected from halogen and OMe;

Ar<sup>5</sup> represents phenyl, a 5- or 6-membered heteroaromatic ring or a quinoline ring; said heteroaromatic ring incorporating 1 to 3 heteroatoms independently selected from O, N and S; said phenyl or heteroaromatic or quinoline ring being optionally further substituted by halogen, C1 to 4 alkyl, CN, C1 to 4 alkoxy, and OCH<sub>2</sub>CH<sub>2</sub>CN;

with the proviso that when R<sup>10</sup> represents halogen, C1 to 4 alkyl, C1 to 4 alkoxy or NH<sub>2</sub>; and Ar represents phenyl; then said phenyl is not substituted at the 4-position by C1 to 2 alkoxy, OH, halogen or C1 to 4 alkyl.

16. (Original) A compound according to Claim 15 that is:

6,7-dichloro-2-[4-(2-morpholin-4-ylethoxy)phenyl]-3*H*-imidazo[4,5-*b*]pyridine

6-chloro-*N*-(2-methoxyphenyl)-2-{4-[2-(4-morpholinyl)ethoxy]phenyl}-1*H*-imidazo[4,5-*b*]pyridin-7-amine

2-[(6-chloro-2-{4-[2-(4-morpholinyl)ethoxy]phenyl}-1*H*-imidazo[4,5-*b*]pyridin-7-yl)amino]phenol

6-chloro-*N*-[1-(methylsulfonyl)-3-pyrrolidinyl]-2-{4-[2-(4-morpholinyl)ethoxy]phenyl}-1*H*-imidazo[4,5-*b*]pyridin-7-amine

6-chloro-*N*-cyclopentyl-2-{4-[2-(4-morpholinyl)ethoxy]phenyl}-1*H*-imidazo[4,5-*b*]pyridin-7-amine

*N*-benzyl-6-chloro-2-{4-[2-(4-morpholinyl)ethoxy]phenyl}-1*H*-imidazo[4,5-*b*]pyridin-7-amine

6-chloro-2-{4-[2-(4-morpholinyl)ethoxy]phenyl}-1*H*-imidazo[4,5-*b*]pyridin-7-amine

6-chloro-2-{4-[2-(4-morpholinyl)ethoxy]phenyl}-7-(1*H*-pyrrol-1-yl)-1*H*-imidazo[4,5-*b*]pyridine

1-(6-chloro-2-{4-[2-(4-morpholinyl)ethoxy]phenyl}-1*H*-imidazo[4,5-*b*]pyridin-7-yl)-3-pyrrolidinamine

1-(6-chloro-2-{4-[2-(4-morpholinyl)ethoxy]phenyl}-1*H*-imidazo[4,5-*b*]pyridin-7-yl)-3-pyrrolidinylformamide

6-chloro-*N*-(2-ethylphenyl)-2-{4-[2-(4-morpholinyl)ethoxy]phenyl}-1*H*-imidazo[4,5-*b*]pyridin-7-amine

6-chloro-7-(2,3-dihydro-1*H*-indol-1-yl)-2-{4-[2-(4-morpholinyl)ethoxy]phenyl}-1*H*-imidazo[4,5-*b*]pyridine

6-chloro-7-(4-morpholinyl)-2-{4-[2-(4-morpholinyl)ethoxy]phenyl}-1*H*-imidazo[4,5-*b*]pyridine

6-chloro-2-[4-(2-morpholin-4-ylethoxy)phenyl]-*N*-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridin-7-amine

[3-(6-chloro-2-[4-(2-morpholin-4-ylethoxy)phenyl]-3*H*-imidazo[4,5-*b*]pyridin-7-yl)amino]phenyl]methanol

6-chloro-*N*-(2-fluorophenyl)-2-[4-(2-morpholin-4-ylethoxy)phenyl]-3*H*-imidazo[4,5-*b*]pyridin-7-amine

6-chloro-2-{4-[2-(4-morpholinyl)ethoxy]phenyl}-*N*-phenyl-1*H*-imidazo[4,5-*b*]pyridin-7-amine

6-chloro-*N*-(3-ethylphenyl)-2-{4-[2-(4-morpholinyl)ethoxy]phenyl}-1*H*-imidazo[4,5-*b*]pyridin-7-amine

2-[benzyl(6-chloro-2-{4-[2-(4-morpholinyl)ethoxy]phenyl}-1*H*-imidazo[4,5-*b*]pyridin-7-yl)amino]ethanol

2-[(6-chloro-2-{4-[2-(4-morpholinyl)ethoxy]phenyl}-1*H*-imidazo[4,5-*b*]pyridin-7-yl)amino]ethanol

*N*-benzyl-6-chloro-*N*-methyl-2-{4-[2-(4-morpholinyl)ethoxy]phenyl}-1*H*-imidazo[4,5-*b*]pyridin-7-amine

6-chloro-*N*-methyl-2-{4-[2-(4-morpholinyl)ethoxy]phenyl}-1*H*-imidazo[4,5-*b*]pyridin-7-amine

7-(benzylthio)-6-chloro-2-{4-[2-(4-morpholinyl)ethoxy]phenyl}-1*H*-imidazo[4,5-*b*]pyridine

6-chloro-*N*-[4-(methylsulfonyl)phenyl]-2-{4-[2-(4-morpholinyl)ethoxy]phenyl}-1*H*-imidazo[4,5-*b*]pyridin-7-amine

6-chloro-2-{4-[2-(4-morpholinyl)ethoxy]phenyl}-*N*-[4-(4-morpholinyl)phenyl]-1*H*-imidazo[4,5-*b*]pyridin-7-amine

*N'*-(6-chloro-2-{4-[2-(4-morpholinyl)ethoxy]phenyl}-1*H*-imidazo[4,5-*b*]pyridin-7-yl)-*N,N*-diethyl-1,4-benzenediamine

*N*-{4-[(6-chloro-2-{4-[2-(4-morpholinyl)ethoxy]phenyl}-1*H*-imidazo[4,5-*b*]pyridin-7-yl)amino]phenyl}acetamide

6-chloro-2-{4-[2-(4-morpholinyl)ethoxy]phenyl}-7-phenoxy-1*H*-imidazo[4,5-*b*]pyridine

6-chloro-2-{4-[2-(4-morpholinyl)ethoxy]phenyl}-7-[2-(1-pyrrolidinyl)ethoxy]-1*H*-imidazo[4,5-*b*]pyridine

6-chloro-2-[4-(2-morpholin-4-ylethoxy)phenyl]-*N*-(2-morpholin-4-ylethyl)-3*H*-imidazo[4,5-*b*]pyridin-7-amine

6-chloro-2-[4-(2-morpholin-4-ylethoxy)phenyl]-7-pyrrolidin-1-yl-3*H*-imidazo[4,5-*b*]pyridine

6-chloro-2-[4-(2-morpholin-4-ylethoxy)phenyl]-*N*-(1-phenylethyl)-3*H*-imidazo[4,5-*b*]pyridin-7-amine

6-chloro-7-(4-methylphenyl)-2-[4-(2-morpholin-4-ylethoxy)phenyl]-3*H*-imidazo[4,5-*b*]pyridine

6-chloro-7-(3-methoxyphenyl)-2-[4-(2-morpholin-4-ylethoxy)phenyl]-3*H*-imidazo[4,5-*b*]pyridine

*N*-(3-{6-chloro-2-[4-(2-morpholin-4-ylethoxy)phenyl]-3*H*-imidazo[4,5-*b*]pyridin-7-yl}phenyl)acetamide

6-chloro-2-[4-(2-morpholin-4-ylethoxy)phenyl]-7-thien-3-yl-3*H*-imidazo[4,5-*b*]pyridine

2-[4-(2-morpholin-4-ylethoxy)phenyl]-3*H*-imidazo[4,5-*b*]pyridine-6,7-dicarbonitrile

7-chloro-2-[4-(2-morpholin-4-ylethoxy)phenyl]-3*H*-imidazo[4,5-*b*]pyridine-6-carbonitrile

7-anilino-2-(4-{2-[(2-methoxyethyl)(methyl)amino]ethoxy}phenyl)-3*H*-imidazo[4,5-*b*]pyridine-6-carbonitrile

6,7-dichloro-2-{4-[2-(4-morpholinyl)ethoxy]-3-nitrophenyl}-1*H*-imidazo[4,5-*b*]pyridine

5-(6,7-dichloro-1*H*-imidazo[4,5-*b*]pyridin-2-yl)-2-[2-(4-morpholinyl)ethoxy]aniline

2-amino-5-(6-chloro-7-methyl-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenol

5-(6-chloro-7-methyl-3*H*-imidazo[4,5-*b*]pyridin-2-yl)-2-{[(2*R*)-pyrrolidin-2-ylmethyl]amino}phenol



[5-(6-chloro-7-methyl-3*H*-imidazo[4,5-*b*]pyridin-2-yl)-2-(2-morpholin-4-ylethoxy)phenyl][(2*R*)-pyrrolidin-2-ylmethyl]amine

4-(6-chloro-7-methyl-3*H*-imidazo[4,5-*b*]pyridin-2-yl)-*N*<sup>1</sup>-(2-morpholin-4-ylethyl)benzene-1,2-diamine

[5-(6-chloro-7-methyl-3*H*-imidazo[4,5-*b*]pyridin-2-yl)-2-(4-methylpiperazin-1-yl)phenyl]amine  
6,7-dichloro-2-[4-(4-morpholinyl)phenyl]-1*H*-imidazo[4,5-*b*]pyridine

[5-(6,7-dichloro-3*H*-imidazo[4,5-*b*]pyridin-2-yl)-2-morpholin-4-ylphenyl]amine

2-(4-aminophenyl)-6-chloro-*N*-phenyl-3*H*-imidazo[4,5-*b*]pyridin-7-amine

*N*-[4-(6,7-dichloro-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]-*N*-(2-morpholin-4-ylethyl)amine

6-bromo-7-methyl-2-[4-(2-piperidin-1-ylethoxy)phenyl]-3*H*-imidazo[4,5-*b*]pyridine

6-bromo-7-methyl-2-(4-nitrophenyl)-1*H*-imidazo[4,5-*b*]pyridine

4-(6-bromo-7-methyl-1*H*-imidazo[4,5-*b*]pyridin-2-yl)aniline

*N*-[4-(6-bromo-7-methyl-1*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]-3-cyanobenzenesulfonamide

*N*-[4-(6-bromo-7-methyl-1*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]-4-cyanobenzenesulfonamide

*N*-[4-(6-bromo-7-methyl-1*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]quinoline-8-sulfonamide

*N*-[4-(6-bromo-7-methyl-1*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]-4-methoxybenzenesulfonamide

*N*-[4-(6-bromo-7-methyl-1*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]-4-(2-cyanoethoxy)benzenesulfonamide

*N*-[4-(6-bromo-7-methyl-1*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]-1-methyl-1*H*-imidazole-4-sulfonamide

*N*-[4-(6,7-dichloro-1*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]-4-methoxybenzenesulfonamide

6-chloro-2-{4-[(2-morpholin-4-ylethyl)amino]phenyl}-*N*-phenyl-3*H*-imidazo[4,5-*b*]pyridin-7-amine

6-chloro-7-methoxy-2-[4-(2-morpholin-4-ylethoxy)phenyl]-3*H*-imidazo[4,5-*b*]pyridine

6-chloro-2-{4-[di(3-cyanobenzyl)amino]phenyl}-7-methoxy-1-yl-3*H*-imidazo[4,5-*b*]pyridine

3-({[4-(6-chloro-7-methoxy-1*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]amino}methyl)benzonitrile)

*N*-[4-(6-chloro-7-methoxy-1*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]-4-cyanobenzenesulfonamide


6-chloro-7-methoxy-2-[4-(2-piperidin-1-ylethoxy)phenyl]-3*H*-imidazo[4,5-*b*]pyridine

or a pharmaceutically acceptable salts thereof.

17. (Cancelled) .

18. (Currently amended) A process for the preparation of a compound of formula (Ia), ~~(Ib)~~, ~~(Ic)~~ or ~~(Id)~~ according to ~~any one of Claims 9 to 16~~ Claim 9 which comprises:


a) reaction of a compound of the general formula (II):



(II)

in which  $\text{R}^3$  and  $\text{R}^{10}$  are as defined in Claim 9 ~~formula (Ia), (Ib), (Ic) or (Id)~~,


with a compound of formula (III):



(III)

in which  $m$ ,  $\text{R}^1$  and  $\text{Ar}$  are as defined in Claim 9 ~~formula (Ia), (Ib), (Ic) or (Id)~~, in the presence of an oxidizing agent; or


b) reaction of a compound of the general formula (II):



(II)

in which  $R^3$  and  $R^{10}$  are as defined in Claim 9 ~~formula (Ia), (Ib), (Ic) or (Id),~~


with a compound of formula (IV):



(IV)

in which  $m$ ,  $R^1$  and Ar are as defined in claim 9 ~~formula (Ia), (Ib), (Ic) or (Id),~~ in the presence of  $POCl_3$ ; or


~~e) reaction of a compound of formula (V):~~



(V)


~~in which  $R^3$ ,  $R^{10}$  and Ar are as defined in formula (Ib), (Ic) or (Id);~~

~~with a compound of formula (VI):~~



~~in which  $R^2$  is as defined in formula (Ib), (Ic) or (Id) and LG represents a leaving group; or~~

d) reaction of a compound of the general formula (VII):



(VII)


in which  $n$ ,  $R^3$ ,  $R^{10}$  and Ar are as defined in Claim 9 ~~formula (Ia) or (Id);~~

with a compound of formula (VIII):




in which  $Ar^2$  is as defined in Claim 9 ~~formula (Ia) or (Id), or~~

~~e) reaction of a compound of the general formula (IX):~~



(IX)

in which  $R^3$ ,  $R^{10}$  and Ar are as defined in formula (Ib) or (Id);  
 with a compound of formula (X):



in which  $R^6$  and  $R^7$  are as defined in formula (Ib) or (Id);

and where desired or necessary converting the resultant compound of formula (Ia), (Ib), (Ic) or (Id) or another salt thereof, into a pharmaceutically acceptable salt thereof; or converting one compound of formula (Ia), (Ib), (Ic) or (Id) into another compound of formula (Ia), (Ib), (Ic) or (Id); and where desired converting the resultant compound of formula (Ia), (Ib), (Ic) or (Id) into an optical isomer thereof.

19. (Currently amended) A pharmaceutical formulation comprising a therapeutically effective amount of a compound of formula (Ia), (Ib), (Ic) or (Id), according to ~~any one of Claims 9 to 16~~ Claim 9, or a pharmaceutically acceptable salt thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier.


20. (New) A pharmaceutical formulation comprising a therapeutically effective amount of a compound of formula (Ib), according to Claim 11, or a pharmaceutically acceptable salt thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier.

21. (New) A pharmaceutical formulation comprising a therapeutically effective amount of a compound of formula (Ic), according to Claim 13, or a pharmaceutically acceptable salt thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier.

22. (New) A pharmaceutical formulation comprising a therapeutically effective amount of a compound of formula (Id), according to Claim 15, or a pharmaceutically acceptable salt thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier.

23. (New) A process for the preparation of a compound of formula (Ib) according to Claim 11 which comprises:


a) reaction of a compound of the general formula (II):



(II)

in which  $R^3$  and  $R^{10}$  are as defined in Claim 11,


with a compound of formula (III):



(III)

in which  $m$ ,  $\text{R}^1$  and Ar are as defined in Claim 11, in the presence of an oxidizing agent; or


b) reaction of a compound of the general formula (II):



(II)

in which  $\text{R}^3$  and  $\text{R}^{10}$  are as defined in Claim 11,


with a compound of formula (IV):



(IV)

in which  $m$ ,  $\text{R}^1$  and Ar are as defined in Claim 11, in the presence of  $\text{POCl}_3$ ; or

c) reaction of a compound of formula (V):



(V)


in which  $R^3$ ,  $R^{10}$  and Ar are as defined in Claim 11;

with a compound of formula (VI):



in which  $R^2$  is as defined in Claim 11 and LG represents a leaving group; or

e) reaction of a compound of the general formula (IX):



(IX)

in which  $R^3$ ,  $R^{10}$  and Ar are as defined in Claim 11;

with a compound of formula (X):






in which  $\text{R}^6$  and  $\text{R}^7$  are as defined in Claim 11;

and where desired or necessary converting the resultant compound of formula (Ib) or another salt thereof, into a pharmaceutically acceptable salt thereof; or converting one compound of formula (Ib) into another compound of formula (Ib); and where desired converting the resultant compound of formula (Ib) into an optical isomer thereof.

24. (New) A process for the preparation of a compound of formula (Ic) according to Claim 13 which comprises:


a) reaction of a compound of the general formula (II):



(II)

in which  $\text{R}^3$  and  $\text{R}^{10}$  are as defined in Claim 13,


with a compound of formula (III):



(III)

in which m, R<sup>1</sup> and Ar are as defined in Claim 13, in the presence of an oxidizing agent; or


b) reaction of a compound of the general formula (II):



(II)

in which R<sup>3</sup> and R<sup>10</sup> are as defined in Claim 13,


with a compound of formula (IV):



(IV)

in which m, R<sup>1</sup> and Ar are as defined in Claim 13, in the presence of POCl<sub>3</sub>; or

c) reaction of a compound of formula (V):



(V)

in which R<sup>3</sup>, R<sup>10</sup> and Ar are as defined in Claim 13;

with a compound of formula (VI):




in which R<sup>2</sup> is as defined in Claim 13 and LG represents a leaving group;

and where desired or necessary converting the resultant compound of formula (Ic) or another salt thereof, into a pharmaceutically acceptable salt thereof; or converting one compound of formula (Ic) into another compound of formula (Ic); and where desired converting the resultant compound of formula (Ic) into an optical isomer thereof.

25. (New) A process for the preparation of a compound of formula (Id) according to Claim 15 which comprises:


a) reaction of a compound of the general formula (II):



(II)

in which R<sup>3</sup> and R<sup>10</sup> are as defined in Claim 15,


with a compound of formula (III):



(III)

in which m, R<sup>1</sup> and Ar are as defined in Claim 15, in the presence of an oxidizing agent; or


b) reaction of a compound of the general formula (II):



(II)

in which R<sup>3</sup> and R<sup>10</sup> are as defined in Claim 15,


with a compound of formula (IV):



(IV)

in which m, R<sup>1</sup> and Ar are as defined in Claim 15, in the presence of POCl<sub>3</sub>; or

c) reaction of a compound of formula (V):



(V)


in which R<sup>3</sup>, R<sup>10</sup> and Ar are as defined in Claim 15;

with a compound of formula (VI):



in which R<sup>2</sup> is as defined in Claim 15 and LG represents a leaving group; or

d) reaction of a compound of the general formula (VII):



(VII)


in which  $n$ ,  $R^3$ ,  $R^{10}$  and Ar are as defined in Claim 15;

with a compound of formula (VIII):



in which  $Ar^2$  is as defined in Claim 15, or

e) reaction of a compound of the general formula (IX):



(IX)

in which  $R^3$ ,  $R^{10}$  and Ar are as defined in Claim 15;

with a compound of formula (X):



in which R<sup>6</sup> and R<sup>7</sup> are as defined Claim 15;

and where desired or necessary converting the resultant compound of formula (Id) or another salt thereof, into a pharmaceutically acceptable salt thereof; or converting one compound of formula (Id) into another compound of formula (Id); and where desired converting the resultant compound of formula (Id) into an optical isomer thereof.